Dongdong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dongdong Li has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Tingting Wang
Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Sichuan Clinical Research Center for Laboratory Medicine, Chengdu, 610041, People's Republic of China
15 shared publications- Chuanmin Tao
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
9 shared publications Lanlan Wang
Division of Clinical Microbiology, Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
6 shared publications- Chuanmin Tao
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
5 shared publications Jingna An
Division of Clinical Microbiology, Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
5 shared publicationsQixia Chen
Division of Clinical microbiology, Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, Republic of China
5 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Diagnostic performance and clinical utility of an HCV antigen-antibody combination assay across diverse real-world cohorts
The traditional two-step serological screening algorithm for hepatitis C virus (HCV) is frequently hindered by diagnostic delays, high molecular testing costs, and high false-positive rates due to non-specific serological interference. The Elecsys HCV Duo assay simultaneously detects HCV core antigen (Ag) and anti-HCV antibodies (Ab); however, comprehensive validation across highly heterogeneous clinical populations, particularly in highly vulnerable groups such as hemodialysis patients, remains limited. This study aimed to evaluate the real-world diagnostic and operational utility of the HCV Duo assay across diverse clinical cohorts. This multi-center study evaluated 1,844 patients stratified into hemodialysis ( n = 856), outpatient ( n = 477), inpatient ( n = 384), and health checkup ( n = 127) settings. Using HCV RNA as the reference standard, the dual-marker assay effectively eliminated 98.8% of low-reactivity (cutoff index [COI] 0.90–3.00) and 44.2% of moderate-reactivity (COI 3.01–10.00) conventional false positives. The Ag module achieved 66.51% overall sensitivity, 99.88% specificity, and a 98.58% positive predictive value. Notably, the assay maintained robust diagnostic reliability against uremia-induced interference in the hemodialysis cohort, where applying a Youden-optimized diagnostic threshold improved Ag sensitivity from 65.0% to 75.0%. Translating these performance metrics into a profile-driven triage strategy safely eliminated the need for routine RNA confirmatory testing in up to 33.3% of the simulated cohort, significantly reducing reliance on downstream molecular analysis. IMPORTANCE: The HCV Duo assay offers simultaneous antigen and antibody detection; however, laboratories lack robust evidence regarding its operational utility across highly diverse patient populations. Consequently, screening protocols remain reliant on delayed and costly RNA confirmation, particularly for complex groups like hemodialysis patients, where uremic interference frequently confounds standard serological testing. This study fills this gap by demonstrating the assay’s robust diagnostic stability across four distinct clinical environments while specifically resolving the long-standing serological blind spot in the hemodialysis cohort. By providing evidence-based, cohort-specific insights and an actionable triage algorithm, this research enables laboratories to implement more efficient, tailored screening pathways. These advances significantly reduce the reliance on unnecessary molecular testing, accelerate clinical decision-making, and provide a pragmatic framework to support global HCV elimination mandates.
- 6 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Open AccessDiagnostic performance and clinical utility of an HCV antigen-antibody combination assay across diverse real-world cohorts
The traditional two-step serological screening algorithm for hepatitis C virus (HCV) is frequently hindered by diagnostic delays, high molecular testing costs, and high false-positive rates due to non-specific serological interference. The Elecsys HCV Duo assay simultaneously detects HCV core antigen (Ag) and anti-HCV antibodies (Ab); however, comprehensive validation across highly heterogeneous clinical populations, particularly in highly vulnerable groups such as hemodialysis patients, remains limited. This study aimed to evaluate the real-world diagnostic and operational utility of the HCV Duo assay across diverse clinical cohorts. This multi-center study evaluated 1,844 patients stratified into hemodialysis ( n = 856), outpatient ( n = 477), inpatient ( n = 384), and health checkup ( n = 127) settings. Using HCV RNA as the reference standard, the dual-marker assay effectively eliminated 98.8% of low-reactivity (cutoff index [COI] 0.90–3.00) and 44.2% of moderate-reactivity (COI 3.01–10.00) conventional false positives. The Ag module achieved 66.51% overall sensitivity, 99.88% specificity, and a 98.58% positive predictive value. Notably, the assay maintained robust diagnostic reliability against uremia-induced interference in the hemodialysis cohort, where applying a Youden-optimized diagnostic threshold improved Ag sensitivity from 65.0% to 75.0%. Translating these performance metrics into a profile-driven triage strategy safely eliminated the need for routine RNA confirmatory testing in up to 33.3% of the simulated cohort, significantly reducing reliance on downstream molecular analysis. IMPORTANCE: The HCV Duo assay offers simultaneous antigen and antibody detection; however, laboratories lack robust evidence regarding its operational utility across highly diverse patient populations. Consequently, screening protocols remain reliant on delayed and costly RNA confirmation, particularly for complex groups like hemodialysis patients, where uremic interference frequently confounds standard serological testing. This study fills this gap by demonstrating the assay’s robust diagnostic stability across four distinct clinical environments while specifically resolving the long-standing serological blind spot in the hemodialysis cohort. By providing evidence-based, cohort-specific insights and an actionable triage algorithm, this research enables laboratories to implement more efficient, tailored screening pathways. These advances significantly reduce the reliance on unnecessary molecular testing, accelerate clinical decision-making, and provide a pragmatic framework to support global HCV elimination mandates.
- 12 February 2026
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (7) , 431-437
Evaluation of three syphilis algorithms: resolving discordance to ensure diagnostic accuracy
Objectives: With the increasing incidence and persistent prevalence of syphilis, it is necessary to reevaluate the clinical utility of three syphilis algorithms. Methods: Cases with concurrent Treponema pallidum -electrochemiluminescence immunoassay (TP-ECLIA), T. pallidum particle agglutination (TPPA) and toluidine red unheated serum test (TRUST) results from a large hospital in China were collected. The diagnostic performance of three syphilis algorithms—the traditional algorithm (start with TRUST and confirmation by TPPA), reverse algorithm 1 (start with TP-ECLIA and confirmation by TRUST with TPPA for TRUST-negative cases) and reverse algorithm 2 (start with TP-ECLIA and confirmation by TPPA with TRUST for TPPA-positive cases)—was evaluated using kappa coefficient analysis and Bayesian latent class model (BLCM), along with assessing their capabilities, discrepancies and limitations in identifying discordant results for T. pallidum antibodies. Results: High agreement was observed between the two reverse algorithms. BLCM revealed sensitivities of 49.1%, 98.9% and 98.5% and specificities of 99.6%, 99.2% and 100.0% for the traditional algorithm, reverse algorithm 1 and reverse algorithm 2. The traditional algorithm identified 11 biological false-positive cases but missed 1177 TPPA + /TRUST − syphilis diagnoses. Discordant treponemal test results (TP-ECLIA + /TPPA −/± ) were common (18.2%) and associated with significantly lower TP-ECLIA cut-off index values. The reverse algorithm 1 identified 500 treponemal test-discordant cases, while the reverse algorithm 2 identified 517 cases. Besides, 17 discordant cases were identified among untested components of the algorithms. Conclusions: The reverse algorithm 2 is recommended, as the confirmation of TP-ECLIA by TPPA reduces the underdiagnosis of previously treated syphilis compared with the traditional algorithm and compensates for the limited specificity of TP-ECLIA, thereby representing an improvement over reverse algorithm 1.
- 12 February 2026
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (7) , 431-437
Evaluation of three syphilis algorithms: resolving discordance to ensure diagnostic accuracy
Objectives: With the increasing incidence and persistent prevalence of syphilis, it is necessary to reevaluate the clinical utility of three syphilis algorithms. Methods: Cases with concurrent Treponema pallidum -electrochemiluminescence immunoassay (TP-ECLIA), T. pallidum particle agglutination (TPPA) and toluidine red unheated serum test (TRUST) results from a large hospital in China were collected. The diagnostic performance of three syphilis algorithms—the traditional algorithm (start with TRUST and confirmation by TPPA), reverse algorithm 1 (start with TP-ECLIA and confirmation by TRUST with TPPA for TRUST-negative cases) and reverse algorithm 2 (start with TP-ECLIA and confirmation by TPPA with TRUST for TPPA-positive cases)—was evaluated using kappa coefficient analysis and Bayesian latent class model (BLCM), along with assessing their capabilities, discrepancies and limitations in identifying discordant results for T. pallidum antibodies. Results: High agreement was observed between the two reverse algorithms. BLCM revealed sensitivities of 49.1%, 98.9% and 98.5% and specificities of 99.6%, 99.2% and 100.0% for the traditional algorithm, reverse algorithm 1 and reverse algorithm 2. The traditional algorithm identified 11 biological false-positive cases but missed 1177 TPPA + /TRUST − syphilis diagnoses. Discordant treponemal test results (TP-ECLIA + /TPPA −/± ) were common (18.2%) and associated with significantly lower TP-ECLIA cut-off index values. The reverse algorithm 1 identified 500 treponemal test-discordant cases, while the reverse algorithm 2 identified 517 cases. Besides, 17 discordant cases were identified among untested components of the algorithms. Conclusions: The reverse algorithm 2 is recommended, as the confirmation of TP-ECLIA by TPPA reduces the underdiagnosis of previously treated syphilis compared with the traditional algorithm and compensates for the limited specificity of TP-ECLIA, thereby representing an improvement over reverse algorithm 1.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 1913-1921
Analysis of Manifestations and Associated Factors of HIV-1 Associated Thrombocytopenia in a General Teaching Hospital in Western China
Background: Thrombocytopenia frequently occurs with HIV-1 infection and plays a vital role in the deterioration of the Blood-Brain Barrier (BBB) and the development of neuroinflammation. This study aims to assess the prevalence and risk factors for HIV-1 associated thrombocytopenia (HAT) and summarize the characteristics of HAT-related neuroinflammation. Methods: A retrospective study of HAT patients was conducted in a general teaching hospital from January 2017 to December 2021. Clinical and laboratory data from HIS and LIS were analyzed to determine the prevalence and risk factors for HAT and manifestations of HAT with neuroinflammation. Results: The prevalence of HAT was 11.06%, with a majority of male patients (76.92%), individuals aged 50 and older (55.21%), and 63.80% experiencing mild thrombocytopenia. Significant differences were observed in CD4+ T cell count, platelet crit (PCT), and the proportion of large platelets (P-LCR) between the HAT and control groups (P< 0.001, P< 0.001, P=0.002). A CD4+ T cell count < 200 cells/μL (P=0.001) was identified as a significant risk factor for HAT, while advanced age and high viral load were closely associated with HAT occurrence. HAT Patients with neuroinflammation were predominantly male (X2=10.066, P=0.007), had higher viral loads (X2=12.297, P=0.006), advanced age (X2=11.721, P=0.02), neuropsychiatric symptoms, and elevated levels of inflammatory factors such as IL-6 and proteins in cerebrospinal fluid (CSF). Conclusion: In HIV-1 infection, the activation of monocytes, macrophages, and microglia leads to thrombocytopenia and neuroinflammation, highlighting the importance of recognizing HAT and HAT with neuroinflammation. Advanced age, lower CD4+ T cell count, and high viral load are closely linked to their occurrence.
- 1 April 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 1913-1921
Open AccessAnalysis of Manifestations and Associated Factors of HIV-1 Associated Thrombocytopenia in a General Teaching Hospital in Western China
Background: Thrombocytopenia frequently occurs with HIV-1 infection and plays a vital role in the deterioration of the Blood-Brain Barrier (BBB) and the development of neuroinflammation. This study aims to assess the prevalence and risk factors for HIV-1 associated thrombocytopenia (HAT) and summarize the characteristics of HAT-related neuroinflammation. Methods: A retrospective study of HAT patients was conducted in a general teaching hospital from January 2017 to December 2021. Clinical and laboratory data from HIS and LIS were analyzed to determine the prevalence and risk factors for HAT and manifestations of HAT with neuroinflammation. Results: The prevalence of HAT was 11.06%, with a majority of male patients (76.92%), individuals aged 50 and older (55.21%), and 63.80% experiencing mild thrombocytopenia. Significant differences were observed in CD4+ T cell count, platelet crit (PCT), and the proportion of large platelets (P-LCR) between the HAT and control groups (P< 0.001, P< 0.001, P=0.002). A CD4+ T cell count < 200 cells/μL (P=0.001) was identified as a significant risk factor for HAT, while advanced age and high viral load were closely associated with HAT occurrence. HAT Patients with neuroinflammation were predominantly male (X2=10.066, P=0.007), had higher viral loads (X2=12.297, P=0.006), advanced age (X2=11.721, P=0.02), neuropsychiatric symptoms, and elevated levels of inflammatory factors such as IL-6 and proteins in cerebrospinal fluid (CSF). Conclusion: In HIV-1 infection, the activation of monocytes, macrophages, and microglia leads to thrombocytopenia and neuroinflammation, highlighting the importance of recognizing HAT and HAT with neuroinflammation. Advanced age, lower CD4+ T cell count, and high viral load are closely linked to their occurrence.
- 21 November 2023
- Published by Wiley in Small Methods
- Vol. 8 (3) , e2300747
A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer
Low‐dose computed tomography screening can increase the detection for non‐small‐cell lung cancer (NSCLC). To improve the diagnostic accuracy of early‐stage NSCLC detection, ultrasensitive methods are used to detect cell‐free DNA (cfDNA) 5‐hydroxymethylcytosine (5hmC) in plasma. Genome‐wide 5hmC is profiled in 1990 cfDNA samples collected from patients with non‐small cell lung cancer (NSCLC, n = 727), healthy controls (HEA, n = 1,092), as well as patients with small cell lung cancer (SCLC, n = 41), followed by sample randomization, differential analysis, feature selection, and modeling using a machine learning approach. Differentially modified features reflecting tissue origin. A weighted diagnostic model comprised of 105 features is developed to compute a detection score for each individual, which showed an area under the curve (AUC) range of 86.4%–93.1% in the internal and external validation sets for distinguishing lung cancer from HEA controls, significantly outperforming serum biomarkers (p < 0.001). The 5hmC‐based model detected high‐risk pulmonary nodules (AUC: 82%)and lung cancer of different subtypes with high accuracy as well. A highly sensitive and specific blood‐based test is developed for detecting lung cancer. The 5hmC biomarkers in cfDNA offer a promising blood‐based test for lung cancer.
- 21 November 2023
- Published by Wiley in Small Methods
- Vol. 8 (3) , e2300747
A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer
Low‐dose computed tomography screening can increase the detection for non‐small‐cell lung cancer (NSCLC). To improve the diagnostic accuracy of early‐stage NSCLC detection, ultrasensitive methods are used to detect cell‐free DNA (cfDNA) 5‐hydroxymethylcytosine (5hmC) in plasma. Genome‐wide 5hmC is profiled in 1990 cfDNA samples collected from patients with non‐small cell lung cancer (NSCLC, n = 727), healthy controls (HEA, n = 1,092), as well as patients with small cell lung cancer (SCLC, n = 41), followed by sample randomization, differential analysis, feature selection, and modeling using a machine learning approach. Differentially modified features reflecting tissue origin. A weighted diagnostic model comprised of 105 features is developed to compute a detection score for each individual, which showed an area under the curve (AUC) range of 86.4%–93.1% in the internal and external validation sets for distinguishing lung cancer from HEA controls, significantly outperforming serum biomarkers (p < 0.001). The 5hmC‐based model detected high‐risk pulmonary nodules (AUC: 82%)and lung cancer of different subtypes with high accuracy as well. A highly sensitive and specific blood‐based test is developed for detecting lung cancer. The 5hmC biomarkers in cfDNA offer a promising blood‐based test for lung cancer.
- 12 January 2021
- Published by BMJ in Sexually Transmitted Infections
- Vol. 97 (7) , 485-489
Diagnostic role of CXCL13 and CSF serology in patients with neurosyphilis
Background: Considering the unknown prevalence of neurosyphilis in West China, and the confusing diagnosis of neurosyphilis, the role of CSF_CXCL13 and syphilis serology was studied to provide a more accurate reference for the clinical detection and diagnosis of neurosyphilis.Methods: A retrospective data set I was used to investigate the prevalence of neurosyphilis, as well as the laboratory characteristics of 244 patients. Besides, to explore the diagnostic value of CSF_CXCL13 and syphilis serology for neurosyphilis, another 116 CSF_serum paired samples (data set II) were collected from 44 neurosyphilis and 72 non-neurosyphilis/syphilis patients.Results: About 6.25% (156 out of 2494) syphilis was neurosyphilis. WhenTreponema palliduminfection occurs, syphilis serology (sero_TRUST ≥1:16 and sero_TPPA titre ≥1:10240) can be good predictors of neurosyphilis, as well as syphilis CSF serology (CSF_TPPA ≥1:320, CSF_TRUST and venereal disease research laboratory). The sensitivity of serology in neurosyphilis can be complemented by CSF_CXCL13, which could be the therapy monitor of neurosyphilis.Conclusion: Due to the lack of ideal biomarkers for neurosyphilis, the importance of syphilis serology cannot be ignored, and their combination with CSF_CXCL13 or other biomarkers should be further investigated.
- 12 January 2021
- Published by BMJ in Sexually Transmitted Infections
- Vol. 97 (7) , 485-489
Diagnostic role of CXCL13 and CSF serology in patients with neurosyphilis
Background: Considering the unknown prevalence of neurosyphilis in West China, and the confusing diagnosis of neurosyphilis, the role of CSF_CXCL13 and syphilis serology was studied to provide a more accurate reference for the clinical detection and diagnosis of neurosyphilis.Methods: A retrospective data set I was used to investigate the prevalence of neurosyphilis, as well as the laboratory characteristics of 244 patients. Besides, to explore the diagnostic value of CSF_CXCL13 and syphilis serology for neurosyphilis, another 116 CSF_serum paired samples (data set II) were collected from 44 neurosyphilis and 72 non-neurosyphilis/syphilis patients.Results: About 6.25% (156 out of 2494) syphilis was neurosyphilis. WhenTreponema palliduminfection occurs, syphilis serology (sero_TRUST ≥1:16 and sero_TPPA titre ≥1:10240) can be good predictors of neurosyphilis, as well as syphilis CSF serology (CSF_TPPA ≥1:320, CSF_TRUST and venereal disease research laboratory). The sensitivity of serology in neurosyphilis can be complemented by CSF_CXCL13, which could be the therapy monitor of neurosyphilis.Conclusion: Due to the lack of ideal biomarkers for neurosyphilis, the importance of syphilis serology cannot be ignored, and their combination with CSF_CXCL13 or other biomarkers should be further investigated.
- Open Access
- 25 August 2020
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (11)
The evaluation of low cut‐off index values of Elecsys® HIV combi PT assay in predicting false‐positive results
Objective: To analyze the results of different cut‐off index (COI) values of Elecsys® HIV combi PT assay and to assess the role of COI in reducing the frequency of false‐positive results.Methods: We conducted a retrospective study of samples analyzed by Elecsys® HIV combi PT assay, a 4th‐generation ECLIA, between 2016 and 2017. A total amount of 379 122 samples were collected for HIV (Human Immunodeficiency Virus) screening.Results: A total of 379 122 samples were analyzed. 2528 (0.67%) were positive by Elecsys® HIV combi PT. Of these, 468 were false‐positive results, and most of them (94.87%) were in samples with 1 < COI < 15. The false‐positive rate was 0.12%. Patients with false‐positive samples were more distributed in elder (P < .001) and female (P < .001) than true‐positive specimens. The median COI in true‐positive specimens was (385.20), which is significantly higher than false‐positive specimens (2.08). The consistency between Elecsys® HIV combi PT assay and 3rd‐generation and positive predictive value (PPV) increased with higher COI values. Cancer, infection, and neurological diseases were considered the potential confounding factors of HIV false‐positive results (19.44%, 11.11%, and 6.62%, respectively).Conclusion: Samples with low COI values, especially those contain confounding factors, need to be further scrutinized to determine whether the confounding factors may cause false‐positive problem. In addition, the hypothesis that low COI values may predict false‐positive results is valid.
- 25 August 2020
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (11)
Open AccessThe evaluation of low cut‐off index values of Elecsys® HIV combi PT assay in predicting false‐positive results
Objective: To analyze the results of different cut‐off index (COI) values of Elecsys® HIV combi PT assay and to assess the role of COI in reducing the frequency of false‐positive results.Methods: We conducted a retrospective study of samples analyzed by Elecsys® HIV combi PT assay, a 4th‐generation ECLIA, between 2016 and 2017. A total amount of 379 122 samples were collected for HIV (Human Immunodeficiency Virus) screening.Results: A total of 379 122 samples were analyzed. 2528 (0.67%) were positive by Elecsys® HIV combi PT. Of these, 468 were false‐positive results, and most of them (94.87%) were in samples with 1 < COI < 15. The false‐positive rate was 0.12%. Patients with false‐positive samples were more distributed in elder (P < .001) and female (P < .001) than true‐positive specimens. The median COI in true‐positive specimens was (385.20), which is significantly higher than false‐positive specimens (2.08). The consistency between Elecsys® HIV combi PT assay and 3rd‐generation and positive predictive value (PPV) increased with higher COI values. Cancer, infection, and neurological diseases were considered the potential confounding factors of HIV false‐positive results (19.44%, 11.11%, and 6.62%, respectively).Conclusion: Samples with low COI values, especially those contain confounding factors, need to be further scrutinized to determine whether the confounding factors may cause false‐positive problem. In addition, the hypothesis that low COI values may predict false‐positive results is valid.
- 9 July 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (12) , 3288-3294
Acute HIV infection in a large teaching hospital in western China: Clinical, virological, and molecular epidemiological characteristics
Objective: To provide information on clinical, virological, and molecular epidemiological characteristics for early identification, diagnosis, and treatment of acute HIV infection (AHI).Methods: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital.Results: A total of 47 patients with AHI were found using a fourth‐generation kit. Thirteen (27.66%) of these patients were negative if tested by third‐generation tests. Median age of patients with AHI was 26 and 91.49% of them were males. Homosexual contact was responsible for 46.81% of AHI transmission. Among the individuals with AHI, 80.85% were outpatients. Common symptoms/signs were fever, headache, rash, cough and sputum, and sore throat. The syphilis coinfection rate was 17.24%. Most of the AHI was distributed in Fiebig stages IV (61.70%) and II (27.66%) with different clinical and virological characteristics. The increasing trend of cut‐off index values was obvious in the course of AHI, helpful for auxiliary diagnosis. The main genetic forms of AHI were CRF07_BC and CRF01_AE, and a rare subtype CRF55_01B in Sichuan province was found. The drug resistance mutation rate was relatively high (17.65%) and five different mutations were identified.Conclusions: Fourth‐generation assays are strongly recommended for screening AHI compared to third‐generation ones. Different clinical and virological characteristics in different Fiebig stages were found. Young individuals and outpatients were the majority of patients with AHI and this deserves special attention. Attention should also be paid to the rare CRF55_01B in Sichuan province and surveillance of HIV resistance ought to be strengthened.
- 9 July 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (12) , 3288-3294
Acute HIV infection in a large teaching hospital in western China: Clinical, virological, and molecular epidemiological characteristics
Objective: To provide information on clinical, virological, and molecular epidemiological characteristics for early identification, diagnosis, and treatment of acute HIV infection (AHI).Methods: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital.Results: A total of 47 patients with AHI were found using a fourth‐generation kit. Thirteen (27.66%) of these patients were negative if tested by third‐generation tests. Median age of patients with AHI was 26 and 91.49% of them were males. Homosexual contact was responsible for 46.81% of AHI transmission. Among the individuals with AHI, 80.85% were outpatients. Common symptoms/signs were fever, headache, rash, cough and sputum, and sore throat. The syphilis coinfection rate was 17.24%. Most of the AHI was distributed in Fiebig stages IV (61.70%) and II (27.66%) with different clinical and virological characteristics. The increasing trend of cut‐off index values was obvious in the course of AHI, helpful for auxiliary diagnosis. The main genetic forms of AHI were CRF07_BC and CRF01_AE, and a rare subtype CRF55_01B in Sichuan province was found. The drug resistance mutation rate was relatively high (17.65%) and five different mutations were identified.Conclusions: Fourth‐generation assays are strongly recommended for screening AHI compared to third‐generation ones. Different clinical and virological characteristics in different Fiebig stages were found. Young individuals and outpatients were the majority of patients with AHI and this deserves special attention. Attention should also be paid to the rare CRF55_01B in Sichuan province and surveillance of HIV resistance ought to be strengthened.
- 1 January 2019
- Published by Elsevier in Clinica Chimica Acta
- Vol. 488, 76-80
Comparison of three syphilis algorithms in West China
- 1 January 2019
- Published by Elsevier in Clinica Chimica Acta
- Vol. 488, 76-80
Comparison of three syphilis algorithms in West China
- 13 June 2018
- Published by Springer Nature in Archives of Virology
- Vol. 163 (10) , 2829-2833
BCP/PC mutation prevalence and their association with HBV replication in HIV/HBV co-infected patients
The high prevalence (14.3%) of HIV/HBV co-infections reported in west China makes it necessary to screen concurrent HBV infection in HIV carriers. HBV B genotype was shown to be dominant in 54 cases of HIV/HBV co-infection, accounting for 81.48% of the total. The total drug resistance rate observed was 3.70%. A1762T, G1764A and G1896A mutations were common mutations identified in the BCP/PC region. However, the prevalence of the G1896A mutation was significantly high among the HBeAg negative HIV/HBV co-infected patients, and may be associated with high HBV replication. Mutations in the PC region are related to the loss in synthesis of HBeAg and may accelerate HBV replication in HIV positive patients.
- 13 June 2018
- Published by Springer Nature in Archives of Virology
- Vol. 163 (10) , 2829-2833
BCP/PC mutation prevalence and their association with HBV replication in HIV/HBV co-infected patients
The high prevalence (14.3%) of HIV/HBV co-infections reported in west China makes it necessary to screen concurrent HBV infection in HIV carriers. HBV B genotype was shown to be dominant in 54 cases of HIV/HBV co-infection, accounting for 81.48% of the total. The total drug resistance rate observed was 3.70%. A1762T, G1764A and G1896A mutations were common mutations identified in the BCP/PC region. However, the prevalence of the G1896A mutation was significantly high among the HBeAg negative HIV/HBV co-infected patients, and may be associated with high HBV replication. Mutations in the PC region are related to the loss in synthesis of HBeAg and may accelerate HBV replication in HIV positive patients.
- 10 January 2018
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 56 (5) , e115-e117
Performance evaluation of a new automated fourth-generation HIV Ag/Ab combination chemiluminescence immunoassay
- 10 January 2018
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 56 (5) , e115-e117
Performance evaluation of a new automated fourth-generation HIV Ag/Ab combination chemiluminescence immunoassay